ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.55
      1.20%
      US Tech 100
      17,092.40
      0.53%
      Dow Jones
      38,503.69
      0.69%
      Brent Oil
      87.345
      -0.25%
      Bitcoin
      66,379.46
      -0.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Altimmune Inc (ALT)

      7. Altimmune Inc (ALT) News

      ALT Altimmune Inc

      7.57
      0.00 (0.00%)
      Pre Market
      Last Updated: 04:57:31
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Altimmune Inc ALT NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      0.00 0.00% 7.57 04:57:31
      Open Price Low Price High Price Close Price Prev Close
      7.57
      more quote information »

      Recent News

      Date Time Source Heading
      3/27/202407:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
      3/27/202406:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
      3/20/202407:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
      2/14/202412:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/14/202406:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/05/202418:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/05/202418:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/05/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/01/202418:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/01/202418:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/01/202418:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/01/202418:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/01/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/29/202418:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/29/202418:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/29/202418:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/29/202418:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/29/202418:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/26/202411:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
      1/04/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/02/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/02/202407:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
      12/08/202308:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
      12/04/202308:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
      11/30/202316:28EDGAR2Form 8-K - Current report
      11/30/202316:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
      11/07/202316:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      11/07/202307:06EDGAR2Form 8-K - Current report
      11/07/202307:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
      10/31/202307:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
      10/26/202308:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
      10/26/202307:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
      10/25/202307:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
      10/17/202307:30GLOBEAltimmune to Participate at Two Upcoming Investor..
      9/29/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      9/29/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      9/29/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      9/29/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      9/29/202317:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      9/28/202316:55EDGAR2Form 8-K - Current report
      9/26/202307:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
      9/12/202307:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
      8/30/202307:30GLOBEAltimmune to Participate at Two Upcoming Investor..
      8/16/202316:14EDGAR2Form ARS - Annual Report to Security Holders
      8/16/202316:10EDGAR2Form DEF 14A - Other definitive proxy statements
      8/15/202318:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      8/10/202316:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      8/10/202307:04EDGAR2Form 8-K - Current report
      8/10/202307:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..
      8/03/202307:30GLOBEAltimmune to Report Second Quarter 2023 Financial Results..

      Your Recent History

      NASDAQ
      ALT
      Altimmune
      Delayed Upgrade Clock